APA (7th ed.) Citation

TL, J., D, B., DM, B., N, C., M, E., C, L., . . . PJ, R. (2017). Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study. JAMA ophthalmology, 135(7), 761. https://doi.org/10.1001/jamaophthalmol.2017.1571

Chicago Style (17th ed.) Citation

TL, Jackson, et al. "Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study." JAMA Ophthalmology 135, no. 7 (2017): 761. https://doi.org/10.1001/jamaophthalmol.2017.1571.

MLA (9th ed.) Citation

TL, Jackson, et al. "Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study." JAMA Ophthalmology, vol. 135, no. 7, 2017, p. 761, https://doi.org/10.1001/jamaophthalmol.2017.1571.